PNRR POC - EVOLUTION Development and validation of a biomedical device for the detection, characterization and removal of Circulating Tumor Cells from the peripheral blood of patients for the treatment and diagnosis of cancer
Funding Agency |
Ministry of Health |
Funding Scheme |
National Recovery and Resilience Plan - Mission 6 - Health |
Component |
C2 - Innovation |
Investment |
2.1 Enhancement and strengthening of biomedical research in the NHS |
Role |
Coordinator |
Operative Unit |
4 |
Budget |
€1.000.000 |
Start date |
17 May 2023 |
Duration |
24 months |
EVOLUTION aims to design, implement and develop a device that is able to treat patients with lung cancer by eliminating circulating tumor cells (CTCs) from the entire blood volume of a patient, during an extracorporeal circulation procedure, giving rise to a treatment that can be defined as "liquid surgery" of the solid tumor.
This project merges innovative patented technological devices/approaches developed at IRST (CTC-sorting unit) and UniSannio (Raman-based detection and characterization unit) in order to define an device that could represent:
a) a therapeutic option that will be used to treat cancers, in addition to conventional strategies, potentially usable in the adjuvant, neoadjuvant and/or metastatic settings, delaying or preventing metastasis onset and spreading, decreasing relapses and deaths;
b) an unprecedented diagnostic chance to investigate tumor features studying a high number of CTCs, even when the tumor cannot be conventionally detected or sampled.
EVOLUTION will pave the way for the therapeutic use of CTC liquid surgery, establishing a novel area of research in the field of cancer research and management and improving CTC based companion diagnostics.